Lizard venom, an eight-year wait, and a patent that expired on a Friday. The short version of how this class of medicine reached India — and why the price did what it did.
There are two ways to understand GLP-1 medication in India. One is the price list. The other is the story of how the price list came to look like that, which is more useful, because it tells you what is likely to happen next.
This is the short version. The full reference — every brand on sale, its manufacturer, its strengths and what each one costs — sits in that article, where the figures are kept in one place and corrected in one place.
It starts with a hormone that lasts two minutes
Your gut releases a hormone called GLP-1 after you eat. It tells the brain you are full and slows how quickly the stomach empties. Researchers worked out its importance in the early 1980s — and immediately hit a wall. Native GLP-1 is broken down by an enzyme within one to two minutes. Fascinating biology, useless medicine.
The way out came from a Gila monster. In 1992, at a Veterans Affairs hospital in the Bronx, John Eng isolated a peptide called exendin-4 from the venom of Heloderma suspectum. It hits the same receptor but resists the enzyme, surviving hours instead of minutes. Every drug in this class since is a variation on solving that same durability problem — twice daily, then once daily, then once weekly, then a tablet.
Each generation also widened the question. Exenatide in 2005 was a diabetes drug. By 2014 a higher-dose liraglutide was approved for weight management specifically. By 2021, semaglutide's obesity results were an effect size previously reserved for bariatric surgery, and the public conversation changed shape entirely. In late 2025 the WHO added GLP-1 therapies to its Essential Medicines List for high-risk type 2 diabetes and issued guidelines on dual agonists for obesity — the formal ratification that obesity is a pharmacologically addressable chronic disease rather than a behavioural failing.
India waited, and then did not
India's version of this timeline is its own thing. Liraglutide arrived here the same year as its global approval. Ozempic took eight years — and landed barely three months before the Indian patent protecting semaglutide expired. Wegovy, the obesity-indication brand, arrived before Ozempic, which tells you something about where the manufacturer thought the Indian demand was.
Then, on 20 March 2026, Indian patent IN 262697 lapsed. Generic semaglutide was on shelves within a day, from Natco, Dr. Reddy's, Sun Pharma, Cipla, Glenmark, Alkem and Zydus. India became the first large market in the world with generic semaglutide — roughly five years ahead of the United States. Twelve days later the originator cut its own Indian prices by 24 to 48 percent across doses.
The result is a market split cleanly in two, and it will stay split. Semaglutide is now close to a commodity here. Tirzepatide is not: its Indian patent runs to roughly 2036, so there is no legal path to an Indian generic before then. Same drug class, completely different economics, for the next decade.
Insurance is not coming to help
As of May 2026, no IRDAI-regulated policy covers GLP-1 medication for obesity — not at Star Health, ICICI Lombard, HDFC ERGO, Niva Bupa or Care Health. Indian health policies were built around inpatient hospitalisation, and an outpatient prescription injectable simply sits outside that architecture. Weight-loss medication is often named as an explicit exclusion rather than merely going unmentioned.
The type 2 diabetes indication is a narrow, partial exception: some diabetes-specific outpatient riders extend to this class when prescribed for documented diabetes by an endocrinologist or diabetologist, adjudicated case by case. Nobody should assume it in advance.
The regulator has shown no signal of mandating coverage in the next eighteen months. The honest expectation is that this stays out of pocket through at least 2027, with generic competition — not insurance reform — setting the floor.
What is actually coming to India
The global pipeline is crowded and most of it is noise from an Indian point of view. Of the next-generation molecules, exactly one has a checkable India signal: orforglipron, a small-molecule oral GLP-1 that needs no cold chain and no injection device. India was a participating site in its global Phase 3 obesity trial and the manufacturer has stated an intent to launch here — though as of August 2026 there is no confirmed filing date, no approval, and no announced India price.
CagriSema, retatrutide and survodutide have no India signal at all. A next-generation drug that is not clearly better than an already-available competitor is unlikely to be prioritised for a market where generic semaglutide already anchors the price.
What this does not tell you
Cheaper is not the same as appropriate. Everything above is about supply, patents and price — none of which says anything about whether this class of medicine is right for a particular person. That question is answered by history, examination and baseline labs, and it is answered by a doctor. See what your doctor checks first and how these medicines actually work.
If you want the numbers themselves — brands, manufacturers, strengths, and what each one costs per dose, per week and per month, with the disputed figures flagged as disputed — they are on the GLP-1 medication reference page.
This article is for general education only. It is not medical advice and not a recommendation to use any medicine named in it. GLP-1 receptor agonists are prescription-only medicines in India and must never be taken without an individual doctor's assessment and ongoing supervision. Brand names appear to identify products accurately, not as endorsements.